A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi w stadium II lub III, potwierdzony badaniem histologicznym
- •Rak piersi dodatni na HER2, potwierdzony badaniem histologicznym
- •Znany status receptorów hormonalnych guza pierwotnego
- •Zgoda na poddanie się operacji piersi (całkowitej lub oszczędzającej) po chemioterapii przed operacją
- •Dobry ogólny stan zdrowia (ECOG 0 lub 1)
- •Prawidłowe funkcjonowanie organów wewnętrznych
- •Funkcja serca na poziomie co najmniej 50% (badanie echokardiograficzne lub MUGA)
- •Zastosowanie odpowiednich środków antykoncepcyjnych
✗ Disqualifies
- •Rak piersi w stadium IV (przerzuty odległe)
- •Rak piersi obustronny
- •Poważne problemy zdrowotne lub stany mogące wpłynąć na udział w badaniu
- •Niekontrolowane wysokie ciśnienie krwi
- •Znaczące objawy uszkodzenia nerwów (neuropatia)
- •Aktywna niekontrolowana infekcja
- •Historia ciężkich alergicznych reakcji na przeciwciała monoklonalne lub białka
- •Aktywne zakaźenie wirusem hepatitis B lub C
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
Oncology Institute
Long Beach, United States
Cancer & Blood Research Center
Los Alamitos, United States
Rocky Mountain Cancer Centers
Denver, United States
Holy Cross Hospital
Fort Lauderdale, United States
The Oncology Institute
Lakeland, United States
Accellacare of McFarland
Ames, United States
LSU Health Sciences Center
Shreveport, United States
New England Cancer Specialists
Scarborough, United States
Maryland Oncology Hematology
Laurel, United States
Cancer Partners of Nebraska
Lincoln, United States
Nebraska Cancer Specialists
Omaha, United States
Astera Cancer Care (Formerly Regional Cancer Care Associates)
East Brunswick, United States
Medical Oncology Hematology Associates
Newark, United States
Hematology Oncology Associates of Central New York
Camillus, United States
Sarah Cannon Research Institute (Nashville)
Nashville, United States
Texas Oncology DFW
Dallas, United States
The University of Texas Southwestern Medical Center
Dallas, United States
Texas Oncology Gulf Coast
Houston, United States
Virginia Cancer Specialists
Fairfax, United States
Virginia Oncology Associates
Norfolk, United States
Shenandoah Oncology
Winchester, United States
Northwest Medical Specialties
Puyallup, United States
Northwest Cancer Specialists
Vancouver, United States
University of Wisconsin
Madison, United States
Ospedale San Raffaele
Milan, Italy
Hospital Clínico San Cecilio
Granada, Spain
Álvaro Cunqueiro Hospital
Vigo, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario Clinico San Cecilio,
Granada, Spain
Hosp Beata María Ana de Jesús
Madrid, Spain
Trial contact
Clinical Trial Disclosure & Transparency
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.